Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07212179 · ClinicalTrials.gov registry record · NA

Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery

A NA study of Type 1 Diabetes, sponsored by Anas El Fathi.

Recruiting
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT07212179: Recruiting NA study of Type 1 Diabetes, sponsored by Anas El Fathi.

NCT07212179 is a NA study of Type 1 Diabetes that is actively recruiting participants, run by Anas El Fathi. The registered enrollment target is 6 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07212179, a NA study of Type 1 Diabetes, is actively recruiting participants, sponsored by Anas El Fathi.

RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

Primary Outcome

The primary outcome will be the CGM-measured time in range (TIR, 70-180 mg/dL) during the hotel portion.

Conditions Studied

Interventions

  • DEVICE AID + InsuLearn-SMA
  • DEVICE AID + CC

Study Locations (1)

Virginia

  • University of Virginia Center for Diabetes Technology - Charlottesville

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2026-03-03
Est. Completion 2026-12-31
Phase NA
Anas El Fathi

1 total trials

What NCT07212179 shows while recruiting

NCT07212179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which AID + InsuLearn-SMA is the first listed.

NCT07212179 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT07212179 about?

NCT07212179 is a clinical study titled "Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery". To evaluate the safety and feasibility of a novel self-learning bolus calculator along with simplified meal announcement (AID+InsuLearn-SMA) in adolescents and young adults with T1D using Automated Insulin Delivery.

What is the current status of trial NCT07212179?

This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2026-03-03. Estimated completion is 2026-12-31.

What conditions does trial NCT07212179 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT07212179?

The interventions under investigation include: AID + InsuLearn-SMA (DEVICE), AID + CC (DEVICE).

Who is sponsoring clinical trial NCT07212179?

This trial is sponsored by Anas El Fathi, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07212179 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07212179's enrollment target sits among peer trials

6 196th of 198 higher than 2 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07212179, the US trial registry maintained by the National Library of Medicine. NCT07212179 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.